Eli Lilly and Co
LLY800.630USD
-17.590-2.14%
Trading geöffnet （ET）Kurse um 15 Minuten verzögert
758.63BMarktkapitalisierung
71.64KGV TTM
mehr Informationen über Eli Lilly and Co Unternehmen
Eli Lilly and Company is a medicine company. The Company discovers, develops, manufactures and markets products in the human pharmaceutical products segment. Its cardiometabolic health products include Basaglar; Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, and others; Humulin, Humulin 70/30, and others; Jardiance; Mounjaro; Trulicity; and Zepbound. Its oncology products include Cyramza, Erbitux, Jaypirca, Retevmo, Tyvyt, and Verzenio. Its immunology products include Ebglyss, Olumiant, Omvoh, and Taltz. Its neuroscience products include Emgality and Kisunla. The Company, through its subsidiary, POINT Biopharma Global Inc., is engaged in radiopharmaceutical discovery, development, and manufacturing efforts, as well as clinical and pre-clinical radioligand therapies in development for the treatment of cancer. It is also developing an oral small molecule inhibitor of α4β7 integrin (known as MORF-057) for inflammatory bowel disease (IBD).
Unternehmensinformationen
Unternehmens-codeLLY
Name des UnternehmensEli Lilly and Co
IPO-datumJul 09, 1970
Gegründet am1901
CEOMr. David A. (Dave) Ricks
Anzahl der mitarbeiter47000
WertpapierartOrdinary Share
GeschäftsjahresendeJul 09
AddresseLilly Corporate Ctr
StadtINDIANAPOLIS
BörseNYSE Consolidated
LandUnited States of America
Postleitzahl46285
Telefon13172762000
Websitehttps://www.lilly.com/
Unternehmens-codeLLY
IPO-datumJul 09, 1970
Gegründet am1901
Führungskräfte
Name
Name/Position
Position
Aktienbesitz
Veränderung
Dr. Daniel M. Skovronsky, M.D., Ph.D.
Dr. Daniel M. Skovronsky, M.D., Ph.D.
Executive Vice President, Chief Scientific Officer and President - Lilly Research Laboratories and Lilly Immunology
Executive Vice President, Chief Scientific Officer and President - Lilly Research Laboratories and Lilly Immunology
212.28K
+12.97%
Ms. Anne E. White
Ms. Anne E. White
Executive Vice President, President - Lilly Neuroscience
Executive Vice President, President - Lilly Neuroscience
74.21K
+13.18%
Mr. J. Erik Fyrwald
Mr. J. Erik Fyrwald
Independent Director
Independent Director
72.69K
+0.02%
Mr. Patrik Jonsson
Mr. Patrik Jonsson
Executive Vice President, President of Lilly Cardiometabolic Health and President, Lilly USA
Executive Vice President, President of Lilly Cardiometabolic Health and President, Lilly USA
54.13K
+20.12%
Ms. Anat Hakim
Ms. Anat Hakim
Executive Vice President, General Counsel, Secretary
Executive Vice President, General Counsel, Secretary
43.54K
+175.92%
Mr. Edgardo Hernandez
Mr. Edgardo Hernandez
Executive Vice President, President - Manufacturing Operations
Executive Vice President, President - Manufacturing Operations
39.75K
+4.13%
Mr. Ilya Yuffa
Mr. Ilya Yuffa
Executive Vice President, President of Lilly International
Executive Vice President, President of Lilly International
28.76K
+45.24%
Dr. Katherine Baicker, Ph.D.
Dr. Katherine Baicker, Ph.D.
Independent Director
Independent Director
23.16K
+0.62%
Mr. Diogo Rau
Mr. Diogo Rau
Executive Vice President, Chief Information and Digital Officer
Executive Vice President, Chief Information and Digital Officer
19.72K
+77.63%
Mr. Lucas E. Montarce
Mr. Lucas E. Montarce
Chief Financial Officer, Executive Vice President
Chief Financial Officer, Executive Vice President
13.97K
+26.18%
Mehr Anzeigen
Name
Name/Position
Position
Aktienbesitz
Veränderung
Dr. Daniel M. Skovronsky, M.D., Ph.D.
Dr. Daniel M. Skovronsky, M.D., Ph.D.
Executive Vice President, Chief Scientific Officer and President - Lilly Research Laboratories and Lilly Immunology
Executive Vice President, Chief Scientific Officer and President - Lilly Research Laboratories and Lilly Immunology
212.28K
+12.97%
Ms. Anne E. White
Ms. Anne E. White
Executive Vice President, President - Lilly Neuroscience
Executive Vice President, President - Lilly Neuroscience
74.21K
+13.18%
Mr. J. Erik Fyrwald
Mr. J. Erik Fyrwald
Independent Director
Independent Director
72.69K
+0.02%
Mr. Patrik Jonsson
Mr. Patrik Jonsson
Executive Vice President, President of Lilly Cardiometabolic Health and President, Lilly USA
Executive Vice President, President of Lilly Cardiometabolic Health and President, Lilly USA
54.13K
+20.12%
Ms. Anat Hakim
Ms. Anat Hakim
Executive Vice President, General Counsel, Secretary
Executive Vice President, General Counsel, Secretary
43.54K
+175.92%
Mr. Edgardo Hernandez
Mr. Edgardo Hernandez
Executive Vice President, President - Manufacturing Operations
Executive Vice President, President - Manufacturing Operations
39.75K
+4.13%
Umsatzaufteilung
Währung: USDUpdate-Zeit: 22 hours ago
Währung: USDUpdate-Zeit: 22 hours ago
FY2024
FY2024Q4
FY2024Q3
FY2024Q2
FY2024Q1
FY2023
FY2023Q4
FY2023Q3
FY2023Q2
FY2023Q1
FY2022
FY2022Q4
FY2022Q3
FY2022Q2
FY2022Q1
FY2021
FY2020
FY2019
Nach GeschäftsbereichUSD
Name
Umsatz
Anteil
Diabetes-Mounjaro
11.54B
25.62%
Oncology-Verzenio
5.31B
11.78%
Diabetes-Trulicity
5.25B
11.66%
Diabetes-Zepbound
4.93B
10.94%
Diabetes-Jardiance
3.34B
7.42%
Other
14.68B
32.58%
Nach RegionUSD
Name
Umsatz
Anteil
U.S.
30.38B
67.44%
Europe
6.92B
15.36%
Other foreign countries
4.27B
9.48%
Japan
1.81B
4.03%
China
1.66B
3.69%
Nach Geschäftsbereich
Nach Region
Nach GeschäftsbereichUSD
Name
Umsatz
Anteil
Diabetes-Mounjaro
11.54B
25.62%
Oncology-Verzenio
5.31B
11.78%
Diabetes-Trulicity
5.25B
11.66%
Diabetes-Zepbound
4.93B
10.94%
Diabetes-Jardiance
3.34B
7.42%
Other
14.68B
32.58%
Aktionäre
Update-Zeit: Fri, Feb 21
Update-Zeit: Fri, Feb 21
Aktionärsstatistik
Art
Aktionärsstatistik
Aktionäre
Anteil
Lilly Endowment, Inc.
10.13%
The Vanguard Group, Inc.
7.80%
PNC Investments LLC
5.39%
BlackRock Institutional Trust Company, N.A.
4.34%
State Street Global Advisors (US)
3.62%
Other
68.73%
Aktionärsstatistik
Aktionäre
Anteil
Lilly Endowment, Inc.
10.13%
The Vanguard Group, Inc.
7.80%
PNC Investments LLC
5.39%
BlackRock Institutional Trust Company, N.A.
4.34%
State Street Global Advisors (US)
3.62%
Other
68.73%
Art
Aktionäre
Anteil
Investment Advisor
37.94%
Investment Advisor/Hedge Fund
25.90%
Foundation
10.22%
Research Firm
1.93%
Pension Fund
1.88%
Bank and Trust
1.79%
Insurance Company
1.43%
Sovereign Wealth Fund
1.24%
Hedge Fund
1.10%
Other
16.57%
Institutionelle Beteiligung
Update-Zeit: Thu, Feb 20
Update-Zeit: Thu, Feb 20
Berichtszeitraum
Anzahl der Institutionen
Gehaltenen Aktien
Anteil
Veränderung
2025Q1
5510
795.05M
83.86%
+1.70M
2024Q4
5528
795.43M
83.87%
+627.51K
2024Q3
5177
793.57M
83.49%
-5.03M
2024Q2
5068
795.80M
83.72%
-2.01M
2024Q1
4916
795.04M
83.62%
-6.22M
2023Q4
4670
799.46M
84.21%
-2.37M
2023Q3
4354
800.21M
84.30%
-1.19M
2023Q2
4197
799.48M
84.22%
-4.32M
2023Q1
4061
801.36M
84.15%
-9.39M
2022Q4
3985
805.64M
84.79%
-7.51M
Mehr Anzeigen
Aktionärsaktivitäten
Name
Gehaltenen Aktien
Anteil
Veränderung
Änderung%
Datum
Lilly Endowment, Inc.
96.02M
10.13%
-220.00K
-0.23%
Mar 03, 2025
The Vanguard Group, Inc.
73.90M
7.8%
+486.78K
+0.66%
Dec 31, 2024
PNC Investments LLC
51.08M
5.39%
-49.68K
-0.10%
Dec 31, 2024
BlackRock Institutional Trust Company, N.A.
41.11M
4.34%
+29.75K
+0.07%
Dec 31, 2024
State Street Global Advisors (US)
34.31M
3.62%
+461.69K
+1.36%
Dec 31, 2024
Fidelity Management & Research Company LLC
29.35M
3.1%
-2.42M
-7.60%
Dec 31, 2024
T. Rowe Price Associates, Inc.
19.73M
2.08%
-77.25K
-0.39%
Dec 31, 2024
Capital World Investors
19.55M
2.06%
-803.44K
-3.95%
Dec 31, 2024
Geode Capital Management, L.L.C.
17.38M
1.83%
+291.88K
+1.71%
Dec 31, 2024
PRIMECAP Management Company
16.76M
1.77%
-933.85K
-5.28%
Dec 31, 2024
Mehr Anzeigen
Verbundene ETFs
Update-Zeit: Wed, Apr 2
Update-Zeit: Wed, Apr 2
Name
Anteil
Defiance Daily Target 2X Long LLY ETF
30.83%
iShares U.S. Pharmaceuticals ETF
25.29%
Amplify Weight Loss Drug & Treatment ETF
18.44%
Roundhill GLP-1 & Weight Loss ETF
18.11%
VanEck Pharmaceutical ETF
14.74%
Proshares Ultra Health Care
13.36%
Health Care Select Sector SPDR Fund
13.35%
iShares U.S. Healthcare ETF
13.16%
Fidelity MSCI Health Care Index ETF
11.93%
Simplify Health Care ETF
11.07%
Mehr Anzeigen
Defiance Daily Target 2X Long LLY ETF
Anteil30.83%
iShares U.S. Pharmaceuticals ETF
Anteil25.29%
Amplify Weight Loss Drug & Treatment ETF
Anteil18.44%
Roundhill GLP-1 & Weight Loss ETF
Anteil18.11%
VanEck Pharmaceutical ETF
Anteil14.74%
Proshares Ultra Health Care
Anteil13.36%
Health Care Select Sector SPDR Fund
Anteil13.35%
iShares U.S. Healthcare ETF
Anteil13.16%
Fidelity MSCI Health Care Index ETF
Anteil11.93%
Simplify Health Care ETF
Anteil11.07%
Dividende
In den vergangenen 5 Jahren wurden insgesamt
18.06B
USD an Dividenden ausgeschüttet.
Datum
Dividende
Stichtag für die Aktienregistrierung
Zahltag
Ex-Dividendentag
Dec 09, 2024
LLY.NB Interim Cash Dividend of gross USD 1.5 paid on Mar 10, 2025 going ex on Feb 14, 2025
Feb 14, 2025
Mar 10, 2025
Feb 14, 2025
Oct 28, 2024
LLY.NB Final Cash Dividend of gross USD 1.3 paid on Dec 10, 2024 going ex on Nov 15, 2024
Nov 15, 2024
Dec 10, 2024
Nov 15, 2024
Jun 24, 2024
LLY.NB Interim Cash Dividend of gross USD 1.3 paid on Sep 10, 2024 going ex on Aug 15, 2024
Aug 15, 2024
Sep 10, 2024
Aug 15, 2024
May 06, 2024
LLY.NB Interim Cash Dividend of gross USD 1.3 paid on Jun 10, 2024 going ex on May 15, 2024
May 16, 2024
Jun 10, 2024
May 15, 2024
Dec 08, 2023
LLY.NB Interim Cash Dividend of gross USD 1.3 paid on Mar 08, 2024 going ex on Feb 14, 2024
Feb 15, 2024
Mar 08, 2024
Feb 14, 2024
Nov 01, 2023
LLY.NB Final Cash Dividend of gross USD 1.13 paid on Dec 08, 2023 going ex on Nov 14, 2023
Nov 15, 2023
Dec 08, 2023
Nov 14, 2023
Jun 26, 2023
LLY.NB Interim Cash Dividend of gross USD 1.13 paid on Sep 08, 2023 going ex on Aug 14, 2023
Aug 15, 2023
Sep 08, 2023
Aug 14, 2023
May 01, 2023
LLY.NB Interim Cash Dividend of gross USD 1.13 paid on Jun 09, 2023 going ex on May 12, 2023
May 15, 2023
Jun 09, 2023
May 12, 2023
Dec 12, 2022
LLY.NB Interim Cash Dividend of gross USD 1.13 paid on Mar 10, 2023 going ex on Feb 14, 2023
Feb 15, 2023
Mar 10, 2023
Feb 14, 2023
Oct 17, 2022
LLY.NB Final Cash Dividend of gross USD 0.98 paid on Dec 09, 2022 going ex on Nov 14, 2022
Nov 15, 2022
Dec 09, 2022
Nov 14, 2022
Mehr Anzeigen
Aktien-Split
Datum
Art
Verhältnis
Keine Daten
Datum
Art
Verhältnis
Keine Daten